ECSP066293A - Combinaciones de un inhibidor de catepsina k y un bisfosfonato en el tratamiento de metástasis ósea, crecimiento de tumor y pérdida ósea inducida por tumor - Google Patents
Combinaciones de un inhibidor de catepsina k y un bisfosfonato en el tratamiento de metástasis ósea, crecimiento de tumor y pérdida ósea inducida por tumorInfo
- Publication number
- ECSP066293A ECSP066293A EC2006006293A ECSP066293A ECSP066293A EC SP066293 A ECSP066293 A EC SP066293A EC 2006006293 A EC2006006293 A EC 2006006293A EC SP066293 A ECSP066293 A EC SP066293A EC SP066293 A ECSP066293 A EC SP066293A
- Authority
- EC
- Ecuador
- Prior art keywords
- tumor
- bone
- treatment
- bone loss
- metallasis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Esta invención se refiere a preparaciones farmacéuticas que comprenden ciertos tipos de bisfosfonatos y ciertos tipos de inhibidores de Catepsina K, en particular en la prevención y tratamiento de metástasis ósea, hipercalcemia inducida por tumor, crecimiento de tumor, pérdida ósea inducida por tumor y enfermedades de pérdida ósea tal como osteoporosis o pérdida ósea inducida por terapia de cáncer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48892503P | 2003-07-21 | 2003-07-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP066293A true ECSP066293A (es) | 2006-07-28 |
Family
ID=34135094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2006006293A ECSP066293A (es) | 2003-07-21 | 2006-01-19 | Combinaciones de un inhibidor de catepsina k y un bisfosfonato en el tratamiento de metástasis ósea, crecimiento de tumor y pérdida ósea inducida por tumor |
Country Status (21)
Country | Link |
---|---|
US (1) | US20060281714A1 (es) |
EP (1) | EP1651238A1 (es) |
JP (1) | JP2006528151A (es) |
KR (1) | KR20060037382A (es) |
CN (1) | CN100406016C (es) |
AR (1) | AR045728A1 (es) |
AU (1) | AU2004262903B2 (es) |
BR (1) | BRPI0412769A (es) |
CA (1) | CA2532948A1 (es) |
CO (1) | CO5680441A2 (es) |
EC (1) | ECSP066293A (es) |
IL (1) | IL172913A0 (es) |
IS (1) | IS8311A (es) |
MA (1) | MA27925A1 (es) |
MX (1) | MXPA06000790A (es) |
NO (1) | NO20060851L (es) |
PE (1) | PE20050328A1 (es) |
RU (1) | RU2006105100A (es) |
TN (1) | TNSN06021A1 (es) |
TW (1) | TW200510436A (es) |
WO (1) | WO2005014006A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070135448A1 (en) * | 2003-11-19 | 2007-06-14 | Martin Missbach | Use of cathepsin k inhibitors for treating of severe bone loss diseases |
GB0427380D0 (en) * | 2004-12-14 | 2005-01-19 | Novartis Ag | Organic compounds |
US20080219996A1 (en) * | 2005-09-26 | 2008-09-11 | Thea Kalebic | Molecular Markers Associated with Bone Metastasis |
US20100331545A1 (en) * | 2007-10-24 | 2010-12-30 | Nippon Chemiphar Co., Ltd. | Regulator for signaling toll-like receptor, which comprises cathepsin inhibitor as active ingredient |
US10590084B2 (en) | 2016-03-09 | 2020-03-17 | Blade Therapeutics, Inc. | Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof |
US11292801B2 (en) | 2016-07-05 | 2022-04-05 | Blade Therapeutics, Inc. | Calpain modulators and therapeutic uses thereof |
CA3038331A1 (en) | 2016-09-28 | 2018-04-05 | Blade Therapeutics, Inc. | Calpain modulators and therapeutic uses thereof |
US20210298890A1 (en) | 2018-06-27 | 2021-09-30 | Cirlo Gmbh | Implants for recruiting and removing circulating tumor cells |
WO2021122803A2 (en) | 2019-12-17 | 2021-06-24 | Cirlo Gmbh | Tubular shaped elongated catheter device assemblies for interacting with components of bodily fluids, method for recovering cells, cell aggregates and exosomes from a tubular shaped elongated catheter device and smart tubular shaped elongated catheter device assemblies for monitoring interaction with components of bodily fluids |
WO2023212104A1 (en) * | 2022-04-27 | 2023-11-02 | The Regents Of The University Of California | Methods and agents for preventing skeletal aging, osteoporosis and obesity |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5501969A (en) * | 1994-03-08 | 1996-03-26 | Human Genome Sciences, Inc. | Human osteoclast-derived cathepsin |
US6544767B1 (en) * | 1994-10-27 | 2003-04-08 | Axys Pharmaceuticals, Inc. | Cathespin O2 protease |
US6017926A (en) * | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
JP2002521450A (ja) * | 1998-07-29 | 2002-07-16 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体アンタゴニスト |
US5998390A (en) * | 1998-09-28 | 1999-12-07 | The Research Foundation Of State University Of New York | Combination of bisphosphonate and tetracycline |
JP2002539190A (ja) * | 1999-03-15 | 2002-11-19 | アクシス・ファーマシューティカルズ・インコーポレイテッド | プロテアーゼ阻害剤としての新規化合物および組成物 |
DE60019580T2 (de) * | 1999-05-21 | 2006-03-09 | Novartis Ag | Verwendung von biphosphonsäuren zur behandlung von angiogenese |
GB0003111D0 (en) * | 2000-02-10 | 2000-03-29 | Novartis Ag | Organic compounds |
US6468559B1 (en) * | 2000-04-28 | 2002-10-22 | Lipocine, Inc. | Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods |
AR036375A1 (es) * | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
CA2466115A1 (en) * | 2001-11-13 | 2003-05-22 | Merck Frosst Canada & Co./Merck Frosst Canada & Cie | Cyanoalkylamino derivatives as protease inhibitors |
-
2004
- 2004-07-20 AU AU2004262903A patent/AU2004262903B2/en not_active Ceased
- 2004-07-20 AR ARP040102560A patent/AR045728A1/es not_active Application Discontinuation
- 2004-07-20 EP EP04741174A patent/EP1651238A1/en not_active Withdrawn
- 2004-07-20 CN CNB2004800211100A patent/CN100406016C/zh not_active Expired - Fee Related
- 2004-07-20 WO PCT/EP2004/008107 patent/WO2005014006A1/en active Application Filing
- 2004-07-20 US US10/565,453 patent/US20060281714A1/en not_active Abandoned
- 2004-07-20 MX MXPA06000790A patent/MXPA06000790A/es not_active Application Discontinuation
- 2004-07-20 BR BRPI0412769-2A patent/BRPI0412769A/pt not_active IP Right Cessation
- 2004-07-20 TW TW093121646A patent/TW200510436A/zh unknown
- 2004-07-20 CA CA002532948A patent/CA2532948A1/en not_active Abandoned
- 2004-07-20 KR KR1020067001370A patent/KR20060037382A/ko not_active Application Discontinuation
- 2004-07-20 JP JP2006520778A patent/JP2006528151A/ja active Pending
- 2004-07-20 PE PE2004000692A patent/PE20050328A1/es not_active Application Discontinuation
- 2004-07-20 RU RU2006105100/04A patent/RU2006105100A/ru not_active Application Discontinuation
-
2005
- 2005-12-29 IL IL172913A patent/IL172913A0/en unknown
-
2006
- 2006-01-18 MA MA28737A patent/MA27925A1/fr unknown
- 2006-01-19 EC EC2006006293A patent/ECSP066293A/es unknown
- 2006-01-20 TN TNP2006000021A patent/TNSN06021A1/en unknown
- 2006-02-17 IS IS8311A patent/IS8311A/is unknown
- 2006-02-21 NO NO20060851A patent/NO20060851L/no not_active Application Discontinuation
- 2006-02-21 CO CO06016980A patent/CO5680441A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2004262903A1 (en) | 2005-02-17 |
CO5680441A2 (es) | 2006-09-29 |
MA27925A1 (fr) | 2006-06-01 |
US20060281714A1 (en) | 2006-12-14 |
IL172913A0 (en) | 2006-06-11 |
CA2532948A1 (en) | 2005-02-17 |
IS8311A (is) | 2006-02-17 |
PE20050328A1 (es) | 2005-06-16 |
MXPA06000790A (es) | 2006-04-07 |
AU2004262903B2 (en) | 2007-08-23 |
CN1826124A (zh) | 2006-08-30 |
BRPI0412769A (pt) | 2006-09-26 |
AR045728A1 (es) | 2005-11-09 |
TNSN06021A1 (en) | 2007-10-03 |
NO20060851L (no) | 2006-04-21 |
JP2006528151A (ja) | 2006-12-14 |
RU2006105100A (ru) | 2007-09-20 |
EP1651238A1 (en) | 2006-05-03 |
WO2005014006A1 (en) | 2005-02-17 |
CN100406016C (zh) | 2008-07-30 |
KR20060037382A (ko) | 2006-05-03 |
TW200510436A (en) | 2005-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP066293A (es) | Combinaciones de un inhibidor de catepsina k y un bisfosfonato en el tratamiento de metástasis ósea, crecimiento de tumor y pérdida ósea inducida por tumor | |
CY1118523T1 (el) | Πεπτιδικες ενωσεις για την θεραπεια του ανθεκτικου status epilepticus | |
CR8410A (es) | Quinolinas utiles en el tratamiento de enfermedades cardiovasculares | |
ATE385797T1 (de) | Phosphonatverbindungen | |
EA201690265A3 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
PT1482924E (pt) | Inibidores de proteases da cisteína catepsina | |
AR033175A1 (es) | Usos farmaceuticos de bisfosfonatos | |
CR11359A (es) | Derivados de pirrolo (2,3-d) pirimidina como inhibidores de proteinas quinasa b | |
EP1372655A4 (en) | CATHEPSINCYSTEIN PROTEASE INHIBITORS | |
BRPI0413255A (pt) | uso de uma combinação de um inibidor de quinase do receptor do fator de crescimento epidérmico e agentes citotóxicos para tratamento e inibição do cáncer | |
ATE232874T1 (de) | Prostaglandin-konjugate zur behandlung von knochenkrankheiten | |
GT200300107A (es) | Tratamiento y prevencion de la osteoporosis | |
CR10304A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
BR0307522A (pt) | Utilização de um inibidor de lipoxigenase-15 para a manufatura de um medicamento, métodos para tratamento e prevenção e kit para o diagnóstico de predisposição à perda óssea | |
CY1109596T1 (el) | Αναστολεις φωσφατασων cdc25 | |
CY1110027T1 (el) | Συνδυασμος ενωσεων πυριμιδυλαμινοβενζαμιδης και ιματινιβης για τη θεραπεια ή την προληψη των νεοπλασματικων ασθενειων | |
BR0313081A (pt) | Combinação de um inibidor de aromatase com um bisfosfanato | |
DK1443942T3 (da) | Farmaceutisk sammensætning til anvendelse ved behandling af maligniteter omfattende en kombination af et bisphosphonat, en COX-2 inhibitor og en taxol | |
CR9539A (es) | 4-anilino-3-quinolinocarbonitrilos para el tratamiento de cancer | |
HUP0301276A2 (hu) | Kombinációs terápia ösztrogénérzékeny betegségek kezelésére | |
ATE412411T1 (de) | Pmcol zur behandlung von prostatakrebs | |
TH70460A (th) | สิ่งที่รวมกันของตัวที่ขัดขวางคะเทพซินเค (Cathepsin K) และบีสฟอสโฟเนท ในการทำการบำบัดมีแทสทาซีสของกระดูกการเติบโตของเนื้องอก และการเสียกระดูกที่ถูกชักนำโดยเนื้องอก | |
CR9064A (es) | Uso de epotilonas en el tratamiento de metastasis en hueso y tumores o tipos de cancer en hueso | |
UA67528A (en) | Method for surgical treatment of thyroid cancer | |
PA8574601A1 (es) | Metodo de administracion o uso de una cantidad terapeuticamente eficaz de fexofendina para el tratamiento de un asma debil |